News and Analysis

The Daily Breakdown dives into what makes up Algorand and Mantle, and then takes a closer look at the technicals for MNT. Before we dive in, let’s make sure you’re set to...

The world’s top investors once again showed their hand. 13-F reports, which detail what stocks investors managing more than $100 million are buying and selling, came out, and...

It's a loaded week of jobs, inflation and retail sales. Plus, Walmart stock is navigating a fresh breakout. The Daily Breakdown dives in. Before we dive in, let’s make sure...

Analyst Weekly, December 15, 2025 Cannabis Stocks: Can 2026 Finally Be a Turning Point? After a difficult few years marked by price pressure, stalled US legislation and heavy...

The German economy is navigating a challenging and complex environment with signs of renewed strength. After weathering energy shocks, supply issues, and geopolitical tensions,...

The Daily Breakdown dives into Meta, which has underperformed the S&P 500 so far in 2025 as investors question its AI spending. Before we dive in, let’s make sure you’re...

The Daily Breakdown dials in after the Fed cut interest rates, and with Broadcom, Lululemon, and Costco set to report earnings. Before we dive in, let’s make sure you’re set to...

The December meeting will mark the last interest rate decision of 2025. Markets expect the Fed to cut and The Daily Breakdown digs in. Before we dive in, let’s make sure you’re...

The Daily Breakdown takes a closer look at the technical setup for Doge, while also exploring Polygon and Arbitrum. Before we dive in, let’s make sure you’re set to receive The...

You’ve more than likely heard of Ozempic, the diabetes drug made by Danish healthcare giant Novo Nordisk and hailed as a miracle weight-loss treatment. GLP-1 weight-loss and...